NCT02603562View on ClinicalTrials.gov

Evaluate Safety and Biological Activity of ATYR1940 in Participants With Early Onset Facioscapulohumeral Muscular Dystrophy

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

March 30, 2016

Primary Completion Date

December 12, 2016

Study Completion Date

December 12, 2016

Conditions
Facioscapulohumeral Muscular Dystrophy (FSHD)
Interventions
BIOLOGICAL

ATYR1940

Concentrate for solution for infusion

Trial Locations (7)

13385

Centre d'nvestigation Clinique - Centre de Pharmacologie Clinique et d'Evaluations Thérapeutiques (CICCPCET), Marseille

20133

Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta, Milan

43210

OSU Wexner Medical Center, Columbus

52242

University of Iowa Children's Hospital, Iowa City

75651

Institut de Myologie, Paris

84132

University of Utah, Salt Lake City

94305

Stanford University, Stanford

All Listed Sponsors
lead

aTyr Pharma, Inc.

INDUSTRY

NCT02603562 - Evaluate Safety and Biological Activity of ATYR1940 in Participants With Early Onset Facioscapulohumeral Muscular Dystrophy | Biotech Hunter | Biotech Hunter